BiomeSense, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BiomeSense, Inc. - overview
Established
2018
Location
Chicago, IL, US
Primary Industry
Biotechnology
About
BiomeSense, Inc. is a biotechnology company specializing in gut microbiome analysis through innovative technology and artificial intelligence, aiming to enhance personalized healthcare solutions. BiomeSense, Inc. was founded in 2018 in Chicago, US, focusing on advanced microbiome analytics.
The company was established by founders Charles Chiu, Jack Gilbert, and Kevin Honaker, with Charles Chiu serving as CEO. BiomeSense has raised a total of USD 3. 00 mn in funding across three deals, with the most recent funding round being a Seed round on May 18, 2023, led by Bluestein Ventures and supported by Harvest Ridge Capital, SOSV, and SEERAVE Foundation. The company's current valuation is USD 16.
706 mn. BiomeSense offers a pioneering suite of products aimed at deciphering the complexities of the gut microbiome using advanced technology and artificial intelligence. Their flagship product, GutLab, allows for continuous monitoring of a patient's gut microbiome by collecting and analyzing microbiome samples throughout their treatment process. This capability enables healthcare providers to create detailed maps of the microbiome, linking these datasets to clinical outcomes.
Additionally, the MetaBiome AI platform employs advanced analytical methods to identify clinically significant shifts in microbiome dynamics, targeting sectors such as research institutions and healthcare providers primarily in North America and Europe. BiomeSense generates revenue mainly through partnerships and collaborations with research institutions and healthcare organizations, providing access to their technology platforms in exchange for contractual fees, structured as either one-time payments or ongoing subscriptions. Their service contracts encompass deliverables associated with the GutLab and MetaBiome technologies, facilitating continuous microbiome data generation and advanced bioinformatics analysis. Following the Seed funding round on May 18, 2023, where BiomeSense raised USD 3.
00 mn, the company plans to utilize this funding to launch the GutLab product within the year. BiomeSense is also focused on expanding its market presence, targeting additional regions in North America and Europe for its innovative microbiome solutions. This strategic growth aims to enhance their offerings and reach a wider audience engaged in personalized medicine and biomarker discovery.
Current Investors
SOSV, IndieBio, BioX Clan
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Analytics & Performance Software, Medical Software
Website
www.biomesenseinc.com
Verticals
Artificial Intelligence, Big Data, HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
BiomeSense, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.